BNET Industries
Last Fiscal Year Sales:$13.3M
- Public
- US
Dow Jones Description
We are a medical aesthetics company focused on developing, manufacturing and commercializing a new category of injectable aesthetic products for the dermatology and plastic surgery markets. On October 27, 2006, the FDA approved ArteFill, our non-resorbable aesthetic injectable implant for the correction of facial wrinkles known as smile lines, or nasolabial folds. Prior to the FDAs approval of ArteFill as the first and only non-resorbable injectable aesthetic product there were two categories of injectable aesthetic products used for the treatment of facial wrinkles: temporary muscle paralytics, which block nerve impulses to temporarily paralyze the muscles that cause facial wrinkles, and temporary dermal fillers, which are injected into the skin or deeper facial tissues beneath a wrinkle to help reduce the appearance of the wrinkle. Unlike existing temporary muscle paralytics and temporary dermal fillers, which are comprised of materials that are completely metabolized and absorbed by the body, ArteFill is a proprietary formulation comprised of polymethylmethacrylate (PMMA) microspheres and bovine collagen, or collagen derived from calf hides. PMMA is one of the most widely used artificial materials in implantable medical devices, and is not absorbed or degraded by the human body. ...
Chief Executive Officer, President and Director
Diane S. GoostreeNumber of Employees 155
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
artes medical inc. - All News and Analysis
Dr. H. Michael Shack, Proxy Organizer, Files Federal Complaint Against Artes Medical, Inc. and Its Board of Directors
NEW YORK -- Dr. H. Michael Shack ("Dr. Shack" or "Proxy Organizer") announced today that he filed a complaint on October 22, 2008 in the United States District Court, Southern District of California, against Artes Medical, Inc. (NASDAQ: ARTE) (the "Company") and its Board of Directors (the "Board") (the "Complaint")....
Securities and Exchange Commission Clears Proxy Statement Filed by Activist Shareholder of Artes Medical, Inc
- Proxy Seeking to Replace Five Board Directors - - Proxy Solicitation Firm to Contact Shareholders to Solicit Votes Ahead of Next Annual Shareholders' Meeting to Be Held on October 30, 2008 - NEW YORK -- Dr. H. Michael Shack, Proxy Organizer and shareholder of Artes Medical, Inc....
Artes Medical, Inc. Receives Nasdaq Notification
SAN DIEGO -- Artes Medical, Inc. (NASDAQ:ARTE), a medical aesthetics company, announced today that it received notice from The Nasdaq Stock Market indicating that its stockholders' equity at June 30, 2008 was less than the $10 million in stockholders' equity required for continued listing on The Nasdaq Global Market under...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Diane S. Goostree | Chief Executive Officer, President and Director |
| Greg J. Kricorian | Chief Medical Officer |
| Harald T. Schreiber | Chief Creative Officer |
| Karla R. Kelly | Chief Legal Officer, General Counsel & Secretary |
| Michael K. Green | Chief Operating Officer & Chief Financial Officer |
| Peter C. Wulff | CFO & Executive Vice President |
| Adelbert L. Stagg | Vice President, Regulatory Affairs & Quality Assurance |
| Frank M. Fazio | Vice President, Marketing & Intl Sales |
| John F. Kay | Vice President, Engineering & Dev |
| Karon J. Morell | Vice President, Regulatory & Quality Affairs |
| Larry J. Braga | Vice President, Manufacturing |
| Russell J. Anderson | Vice President, New Products Engineering |
| Susan A. Brodsky-Thalken | Vice President, Sales & Trng |
| William Von Brendel | Vice President, Worldwide Sales & Marketing |
| Mira Habel | Controller |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Daren J. Barone | Chairman |
| Beverly A. Huss | Board of Directors |
| Christopher J Reinhard | Board of Directors |
| Douglas Abel | Board of Directors |
| John Costantino | Board of Directors |
| Lon E. Otremba | Board of Directors |
| Robert B. Sherman | Board of Directors |
| Todd C. Davis | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| SkinMedica, Inc. | Senior Vice President, Corp Development | Current |
| Artes Medical Inc | Chief Executive Officer, President and Director | Current |
| Artes Medical Inc | Board of Directors | Current |
| Elan Pharmaceuticals, Inc. | Vice President, Business Development | Former |
| SkinMedica, Inc. | Consultant | Former |
| Dura Pharmaceuticals, Inc. | Former | |
| University of Missouri | M.B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Chief Medical Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Chief Creative Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Chief Legal Officer, General Counsel & Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Chief Operating Officer & Chief Financial Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | CFO & Executive Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, Regulatory Affairs & Quality Assurance | Current |
| Allergan, Inc. | Board of Directors | Former |
| Duke University | Ph.D. | Former |
| Andrews University | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, Marketing & Intl Sales | Current |
| A M C Consulting Ltd | Principal | Former |
| The University of Arizona | B.S. In Molecular and Cellular Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, Engineering & Dev | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, Regulatory & Quality Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, Manufacturing | Current |
| California State University | B.S. In Biological Sciences | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, New Products Engineering | Current |
| Novare Surgical Systems, Inc. | Director of Engineering | Former |
| Target Therapeutics | Product Development Consultant | Former |
| NuVasive, Inc. | Project Engineer | Former |
| California State University | M.B.A. | Former |
| California Polytechnic State University | B.S. In Environmental Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, Sales & Trng | Current |
| Aap, Inc. | Principal | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Vice President, Worldwide Sales & Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Controller | Current |
| Organization | Position | Status |
|---|---|---|
| The Barone Group | Chief Executive Officer | Current |
| Artes Medical Inc | Chairman | Current |
| Watkins Contracting, Inc. | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Board of Directors | Current |
Mr. Reinhard is a co-founder of Cardium and has served as a director and the Chief Executive Officer, President and Treasurer of Cardium since its inception in December 2003. Mr. Reinhard has also served as a director and the Chief Executive Officer and Treasurer of InnerCool Therapies, Inc. since March 2006, and as a director and the Chief Executive Officer and President of Tissue Repair Company since August 2006, each a wholly-owned subsidiary of Cardium. Previously, he served as a director and the Chief Executive Officer, President and Treasurer of Aries Ventures Inc. from October 20, 2005 through its merger with Cardium in January 2006. He also served as Chief Financial Officer of Aries Ventures Inc. from October 20, 2005 to November 16, 2005. For the past ten years, Mr. Reinhard has focused on the commercial development of cardiovascular growth factor therapeutics. Before founding Cardium, he was a co-founder of Collateral Therapeutics, Inc., a former Nasdaq listed public company, and served as a director (from 1995) and President (from 1999) of Collateral Therapeutics until the completion of its acquisition by Schering AG Group, Germany (Schering) in 2002. He continued as Chief Executive of Collateral Therapeutics through December 2004. Mr. Reinhard played a major role in effecting Collateral Therapeutics' initial public offering led by Bear Stearns & Co. in 1998, and the sale of Collateral Therapeutics to Schering. Mr. Reinhard has also been Executive Chairman (since 2004) of Artes Medical, Inc., a publicly-traded medical technology company. Previously, Mr. Reinhard was Vice President and Managing Director of the Henley Group, a publicly-traded diversified industrial and manufacturing group, and Vice President of various public and private companies created by the Henley Group through spin-out transactions, including Fisher Scientific Group, a leading international distributor of laboratory equipment and test apparatus for the scientific community, Instrumentation Laboratory and IMED Corporation, a medical device company. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College.
| Organization | Position | Status |
|---|---|---|
| Tissue Repair Company | Chairman and Chief Executive Officer | Current |
| Innercool | Chairman and Chief Executive Officer | Current |
| Cardium Therapeutics, Inc | Chairman of The Board, Chief Executive Officer, President and Treasurer | Current |
| Cardium Therapeutics, Inc | Co-Founder | Current |
| Cardium Therapeutics, Inc | Director | Current |
| Artes Medical Inc | Board of Directors | Current |
| Collateral Therapeutics, Inc. | Chief Executive Officer | Former |
| Collateral Therapeutics, Inc. | President | Former |
| Collateral Therapeutics, Inc. | Chief Executive | Former |
| The Henley Group | Vice President | Former |
| Instrumentation Laboratory | Vice President of Various Public | Former |
| The Henley Group | Managing Director | Former |
| Collateral Therapeutics, Inc. | Co-Founder | Former |
| Instrumentation Laboratory | International Distributor | Former |
| Tissue Repair Company | Director | Former |
| Innercool | Director | Former |
| Collateral Therapeutics, Inc. | Director | Former |
| Babson College | M.B.A. | Former |
| Babson College | B.S. In Finance | Former |
| Organization | Position | Status |
|---|---|---|
| Manhattan Pharmaceuticals, Inc. | President, Chief Executive Officer and Director | Current |
| Manhattan Pharmaceuticals, Inc. | Chairman | Current |
| Artes Medical Inc | Board of Directors | Current |
| Biogen Idec, Inc. | Vice President of the Dermatology Business Unit | Former |
| Biogen, Inc. | Former | |
| Temple University | MBA | Former |
| Lafayette College | Ab In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| NGN Capital | Managing General Partner | Current |
| Walden Capital Partners, L.P. | Principal | Current |
| Enzybiotics, Inc. | Chairman | Current |
| Artisan Pharma, Inc. | Director | Current |
| Ameriscape Inc. | Director | Current |
| Bemiss-Jason | Director | Current |
| Medrium, Inc | Director | Current |
| Artes Medical Inc | Board of Directors | Current |
| Fordham University | Board Member | Current |
| Act Biotech, Inc. | Board of Directors | Current |
| Walden Capital Partners, L.P. | Principal and Advisory Committee Member | Current |
| Conair Corporation | Coo | Former |
| Conair Corporation | Senior Executive Vice President | Former |
| Touche Ross & Co. | Senior Tax Partner | Former |
| Greenberg, Inc. | Partner | Former |
| Fordham University | Certified Public Accountant | Former |
| Wells Fargo Mortgage, Inc. | Former | |
| Republic National Bank | Advisory Member | Former |
| Conair Corporation | Director | Former |
| Fordham University | J.D. | Former |
| Fordham University Law School | J.D. | Former |
| Fordham University | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Strategic-LP | Principal Managing Partner | Current |
| Access 360 Media, Inc | Current | |
| Power Medical Interventions, Inc. | Board of Directors | Current |
| Tissue Repair Company | Board of Directors | Current |
| Artes Medical Inc | Board of Directors | Current |
| Buckley Country Day School | Treasurer | Current |
| Eei Communications | Board of Directors | Current |
| Cardium Therapeutics, Inc | Board of Directors | Current |
| Muzak, LLC | Chief Executive Officer | Former |
| Mail.com Media Corporation | Chief Executive Officer | Former |
| Mail.com Media Corporation | President | Former |
| Muzak, LLC | Director | Former |
| Mail.com Media Corporation | Director | Former |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Artes Medical Inc | Board of Directors | Current |
Executive News
-
Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate...
-
Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

